Login to Your Account

Pharma: Other News To Note

Friday, February 10, 2012
• Merck and Co. Inc., of Whitehouse Station, N.J., warned U.S. physicians that a recent pharmacokinetic study in healthy volunteers showed hepatitis C protease inhibitor Victrelis (boceprevir) may reduce the efficacy of ritonavir-boosted HIV protease inhibitors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription